Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10210773 | 0.80 | HPGD (0.63) | HPGDTSHRALDH1A1KMT2AMAPT | |
| SCHEMBL23714486 | 0.77 | HPGD (0.63) | HPGDTSHRALDH1A1KMT2AKDM4E | |
| SCHEMBL2937860 | 0.77 | HPGD (0.63) | HPGDTSHRALDH1A1KMT2A | |
| SCHEMBL12545612 | 0.76 | HDAC4 (0.42) | HPGDALDH1A1KDM4EMAPT | |
| SCHEMBL4431567 | 0.76 | HPGD (0.66) | HPGDTSHRALDH1A1KDM4EMAPT | |
| SCHEMBL6738518 | 0.76 | TSHR (0.96) | HPGDTSHRALDH1A1KMT2AKDM4E | |
| SCHEMBL25820331 | 0.74 | HDAC4 (0.41) | HPGDALDH1A1KDM4EMAPT | |
| SCHEMBL9612077 | 0.74 | TSHR (1.00) | HPGDTSHRALDH1A1KMT2AKDM4E | |
| SCHEMBL3936704 | 0.74 | TSHR (1.00) | HPGDTSHRALDH1A1KMT2AKDM4E | |
| SCHEMBL12278157 | 0.74 | ALDH1A1 (0.63) | TSHRALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586751-B2 | Nicotinamide compounds useful as kinase modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MEYERS SQUIBB COMPANY | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120082702-A1 | NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS | NADK, BTK, NAMPT | HPGD 225/4885TSHR 3658/4885ALDH1A1 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.